ArticleFrontiers in oncology2026
Case Report: Late repeat pancreatic irreversible electroporation in the long-term multidisciplinary management of unresectable pancreatic ductal adenocarcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unresectable locally advanced pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, particularly after distant metastasis. Irreversible electroporation (IRE) is a nonthermal ablative technique used for pancreatic tumors adjacent to major vessels, but evidence on late repeat pancreatic IRE remains limited. We report a 62-year-old man who presented with obstructive jaundice. Multidisciplinary evaluation classified the tumor as unresectable locally advanced PDAC involving the superior mesenteric vein-portal vein confluence. In January 2021, he underwent pancreatic IRE with biliary bypass, followed by sequential systemic therapy. Liver metastases developed approximately 10 months later and were treated locally, after which he continued multimodal therapy. In April 2025, gastroscopy revealed deformity and luminal narrowing of the duodenal bulb, accompanied by gastric retention, for which laparoscopic gastrojejunostomy was performed. In late 2025, a marked rise in carbohydrate antigen 19-9 (CA19-9) and tumor progression prompted multidisciplinary reassessment. Nearly 5 years after the initial procedure, he underwent repeat pancreatic IRE combined with radiofrequency ablation of a hepatic metastasis. During subsequent multimodal management, CA19-9 decreased from 12,280.0 to 291.4 U/mL. As of March 2026, he remained alive with disease, with an overall survival exceeding 62 months. This case demonstrates the technical feasibility of repeat pancreatic IRE after a prolonged interval and supports its potential role as an individualized local treatment within long-term multidisciplinary management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.